ReviewImmunotherapy2025

The use of durvalumab and tremelimumab after atezolizumab and bevacizumab in patients with hepatocellular carcinoma: case report and literature review.

Maen Abdelrahim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.